GNI And EpiCept Ink Development Deal For Anti-Viral Hepatitis B Drug
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - GNI and EpiCept have entered into an agreement that will see the latter develop a new anti-viral hepatitis B drug, EP1013, in Asia, Australia and New Zealand
You may also be interested in...
China’s Biopharma Sector Enjoys 20% Growth
Western partners underestimate resources needed to establish quality processes, understand mind-sets in Chinese industry, thought leader says.
China’s Biopharma Sector Enjoys 20% Growth
Western partners underestimate resources needed to establish quality processes, understand mind-sets in Chinese industry, thought leader says.
China’s Biopharma Sector To Grow At 20 Percent - Study
SHANGHAI - The Chinese biopharmaceutical sector continues to grow by 20 percent each year, according to a study published in August by BioPlan Associates and the Society for Industrial Microbiology